Abstract Number: PB0457
Meeting: ISTH 2020 Congress
Background: Several biomarkers are associated with the occurrence of venous thromboembolic events (VTE) in cancer patients but the role of inflammation and hemostasis dysregulation in pathophysiology of VTE in lymphoma patients is not clarified yet.
Aims: The aim of this study was to profile hemostatic and inflammatory biomarkers in patients with aggressive and indolent non Hodgkin and Hodgkin lymphoma and to validate potential connection with development of thrombotic events.
Methods: Plasma samples were collected from lymphoma patients (n=62) treated at Clinic for hematology, Lymphoma Center, Clinical Center Serbia. Samples were analyzed to profile biomarkers of coagulation activation (von Willebrand Factor (vWF), Factor XIIIa, Protein S, β2Glycoprotein I (β2GPI), D-dimer, Microparticles (MP), Urokinase-type Plasminogen Activator Antigen (uPA), Fibronectin) and inflammation (Human Tumor Necrosis Factor- α (TNF-α), C-Reactive Protein (CRP), Plasminogen Activator Inhibitor Type 1 (PAI-1)). The lymphoma patient population for each biomarker was compared to normal human pooled plasma.
Results: We analysed 41 patients (66.1%) with aggressive non-Hodgkin lymphoma (NHL), 13 (21%) with indolent NHL and 8 (12.9%) with Hodgkin lymphoma (HL). All three groups of lymphoma patients had significantly higher following markers of coagulation (vWF, d-dimer, Factor XIIIa fibronectin) and inflammation (PAI-1 and CRP) compared to healthy controls, except indolent NHL and Hodgkin lymphoma to PAI and vWf, respectively (Figure 1). In lymphoma population 10 patients had thrombosis. Patients with thrombosis had significantly higher Factor XIIIa in comparison to lymphoma patients without thrombosis (103.1 (range 94.6-122.1) vs. 91.3 (range 24.4-128.6) %; p< 0.005).
Conclusions: This study confirmed significant hemostatic dysregulation and inflammation in our group of lymphoma patients, which may reflect increased thrombogenic potential. Further studies are required to link clinical data and biomarker levels, with special emphasis on the involvement of FXIII in the development of thrombotic events in lymphoma patients.
To cite this abstract in AMA style:Antic D, Otasevic V, Bontekoe E, Siddiqui F, Hoppensteadt D, Baig N, Sinacore J, Djurasinovic V, Vukovic V, Tomic K, Mihaljevic B, Fareed J. Analysis of Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma Patients [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/analysis-of-biomarkers-of-hemostatic-dysregulation-and-inflammation-in-lymphoma-patients/. Accessed January 27, 2022.
« Back to ISTH 2020 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/analysis-of-biomarkers-of-hemostatic-dysregulation-and-inflammation-in-lymphoma-patients/